CDC Study Shows SpectRx Continuous Glucose Monitor Tracks Glucose Levels in Children and Adults.

Business Editors/Health/Medical Writers

NEW ORLEANS--(BUSINESS WIRE)--June 16, 2003

Results of a study presented at the American Diabetes Association's (ADA) 63rd Scientific Session indicate that continuous glucose prototypes developed by SpectRx, Inc. (NASDAQ: SPRX) monitor the levels of glucose in children as well as in adults. The study, sponsored by the U.S. Centers for Disease Control and Prevention (CDC), was designed to test the performance of the monitor in a diverse pediatric population.

"The ability to continuously monitor glucose should become an important component of controlling diabetes in both children and adults," said Peter Chase, M.D., principal investigator of the CDC study. "Based on the study conclusions, we feel that the SpectRx system potentially could have a beneficial impact on the management of diabetes in children and adults."

"We are very encouraged by the results of this study of children using a SpectRx continuous sensor and the conclusions provide valuable information as we continue our efforts to commercialize this technology," said Mark A. Samuels, chairman and CEO of SpectRx, Inc. "We believe that continuous glucose monitoring will be a valuable tool in the successful management of diabetes for potentially millions of people."

The study was carried out on 50 children between the ages of seven and 17 years old at the Barbara Davis Center for Childhood Diabetes in Denver, and was designed to determine if there were significant differences in device performance in a pediatric population versus an adult population. The range of glucose levels measured in the study was 40 mg/dL to 400 mg/dL. Of the devices that tracked, 91% of the readings were within the clinically acceptable Clarke Error Grid A and B zones when compared to blood readings. Eighty-seven percent of the devices tracked on day one, and 71% of the devices tracked on day two. Additionally, adequate fluid flow was reported in virtually all study participants.

The SpectRx technology measures glucose levels in transdermal body fluid (TDF). TDF is the clear fluid under the skin through which glucose and other nutrients travel from the blood stream to the cells. The TDF is collected through an array of microscopic holes, or micropores, created with a laser in the outer layer of skin, and measured with a glucose sensor. The technology may be adapted to measure glucose continuously or periodically. In addition to glucose, other compounds found in the body may be measured using the technology.

Blood glucose levels are a measure of an individual's health status. Because people with diabetes cannot properly metabolize glucose, they typically monitor their glucose levels by frequently pricking their fingertips to draw the drop of blood necessary for conventional glucose monitoring. The estimated annual blood glucose monitoring market is $4.5 billion worldwide.

About SpectRx

SpectRx, Inc. (NASDAQ: SPRX) is a medical technology company providing innovative detection, monitoring and treatment solutions for the diabetes and cancer healthcare markets. SpectRx is currently marketing its SimpleChoice(R) line of innovative diabetes management products, which include insulin pump disposable supplies and over-the-counter diabetes testing kits. These FDA-cleared products complement its developmental consumer device for continuous glucose monitoring. SpectRx is also applying its leading-edge biophotonic technology to the early detection of cancer. Products under development include devices to detect and guide treatment of cervical cancer and skin cancer. The combined market opportunity for SpectRx's products is approximately $7 billion annually. For more information, visit SpectRx's web sites at www.spectrx.com and www.mysimplechoice.com.

Note to Editors: Images of the SpectRx glucose monitoring technology may be found at http://www.spectrx.com/images.asp.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this report that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from SpectRx's actual future experience involving any of or more of such matters and subject areas. SpectRx has attempted to identify, in context, certain of the factors that they currently believe may cause actual future experience and results to differ from SpectRx's current expectations regarding the relevant matter or subject area. Such risks and uncertainties include: the ability of the Company to continue as a going concern, the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time in SpectRx's reports under the heading "Risk Factors" filed with the SEC, including SpectRx's Annual Report on Form 10-K for the fiscal year ended December 31, 2002 and subsequent quarterly reports.